biosimilars
Policy shift needed to boost biosimilar uptake: Halton
Boosting uptake of biosimilars will require practitioner change and a policy rethink, GBMA chair says Australia is “underdone on penetration in the market” when it comes to uptake of biosimilar medications, …
Halve the PBS co-payment for biosimilars: GBMA
Reducing out-of-pocket costs and strengthening biosimilar uptake will deliver savings for people struggling with cost of living, says leading association The Generic and Biosimilar Medicines Association (GBMA) has proposed three …
PBS biosimilar drive more important than ever
Two new representatives have been welcomed to the GBMA Board, including a former pharmacist The Generic and Biosimilar Medicines Association Independent Chair, Professor Jane Halton and CEO, Marnie Peterson, welcomed …
‘The confidence is not there.’
Biosimilar switching and even administration will be significant parts of full scope of practice – but pharmacists need confidence, says a sector leader Pharmacy stakeholders went to Parliament House, Canberra …
A new recommendation
PBAC recommends listing of adalimumab biosimilar The PBAC has recommended the Authority Required listing of adalimumab (Yuflyma) in the form of 40 mg in 0.4 mL pre-filled syringe and pre-filled …
Biosimilars: still a work in progress
Evidence is pointing to most pharmacists still struggling to come to grips with their role in providing biosimilar medicines It’s now been seven years since the Pharmaceutical Benefits Advisory Committee …
Pfizer sues pharmas over arthritis drug patent
If successful, action could hit pharmacy dispensed biosim Brenzys Multinational pharmaceutical giant Pfizer is suing four other drug companies over allegedly breaching a patent for its rheumatoid arthritis treatment Enbrel …
Gerald Tracey: Collaborative care and supporting the transition to biosimilars
Rheumatologist, Dr Gerald Tracey explains the opportunities biosimilars present for prescribing physicians, particularly given the government supported streamlined process. Gerald highlights the advantages of collaborative care between the prescriber and …
Trent Twomey: The role of pharmacists and physicians in supporting a patient-centric narrative
Trent Twomey, the National President of the Pharmacy Guild of Australia highlights the shifting power dynamic from physicians to patients in determining what medicines they are prescribed. Collaborative care is …
Andrew Oster: The power of collaborative care in transitioning to biosimilars
Professor Andrew Oster, Consultant Rheumatologist at the Cabrini Medical Centre in Malvern, Victoria, explains the opportunities biosimilars bring, allowing patients to switch medications. Given the interchangeability of biosimilars, he emphasises …
Eric Chan: Cultivating a relationship of trust between pharmacist and physician
Head of Pharmacy at Blooms The Chemist, Eric Chan emphasises the importance of collaborative care in cultivating a relationship of trust and transparency between a pharmacist and physician. He outlines …
George Tambassis: Empowering and educating pharmacists on biosimilars
George Tambassis, Pharmacist, ex-National Guild President, and chair of the Australian Biosimilar Academy Advisory Board outlines the importance of pharmacist involvement in understanding biosimilars. Given the government supported Community Pharmacy …